TVTXTravere Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $491M
- 110% YoY
- Operating margin
- -12.8%
- 91% YoY
- EBITDA
- −$2M
- 99% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$95M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $132M | $109M | $145M | $233M | $491M | 110% |
| Operating income | −$199M | −$320M | −$388M | −$324M | −$63M | 81% |
| Net income | −$180M | −$278M | −$111M | −$322M | −$26M | 92% |
| Operating cash flow | −$15M | −$186M | −$280M | −$237M | $38M | 116% |
| Capex | $5M | $191K | $668K | — | — | |
| Stock-based comp | $30M | $38M | $44M | $37M | $45M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $79M · 43
- Net
- −$79M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $24M | 140 | 125 |
| FY2024 | $5M | $11M | 123 | 118 |
| FY2023 | $8M | $885K | 63 | 119 |
| FY2022 | $6M | $687K | 148 | 114 |
| FY2021 | $6M | $7M | 219 | 126 |